Search

Displaying results 4451 - 4460 of 5504 in total
  1. Drug

    Canertinib

    go.drugbank.com/drugs/DB05424
    Investigational

    Canertinib treatment significantly affects tumour metabolism, proliferation and hypoxia as determined by PET.

  2. Drug

    Vibriolysin

    go.drugbank.com/drugs/DB05135
    Experimental

    It is a new agent for enzymatic debridement, shown to rapidly and thoroughly hydrolyze burn wound eschar within full-thickness wounds.

  3. Drug

    beta-Naphthoflavone

    go.drugbank.com/drugs/DB06732
    Experimental

    It may be a chemopreventive agent.

  4. Drug

    Nesvacumab

    go.drugbank.com/drugs/DB15330
    Investigational

    Nesvacumab is under investigation in clinical trial NCT01997164 (Study of Intravitreal (IVT) REGN910-3 and IVT REGN910 in Patients With Either Neovascular (Wet) Age Related Macular Degeneration (AMD) or

  5. Drug

    AVXS-301

    go.drugbank.com/drugs/DB17943
    Experimental

    It is being investigated for the treatment of Amyotrophic Lateral Sclerosis (ALS).[L47077]

  6. Drug

    Valoctocogene roxaparvovec

    go.drugbank.com/drugs/DB15561
    ApprovedInvestigationalWithdrawn

    It is not approved for use in the United States.

  7. Drug

    Human interferon omega-1

    go.drugbank.com/drugs/DB05472
    Investigational

    It occurs naturally in the human body and is currently being manufactured by Intarcia through genetic engineering. … It has been investigated both in single and combination treatment. The biological activities of IFN-omega 1 and its physiological role are not known to date.

  8. Drug

    Tanaproget

    go.drugbank.com/drugs/DB04787
    Experimental

    It is currently in the process of being developed for clinical use as a contraceptive by Ligand Pharmaceuticals. … It is a high affinity, high efficacy agonist of the progesterone receptor (PR) with a much more selective binding profile relative to most conventional progestins.

  9. Drug

    PS386113

    go.drugbank.com/drugs/DB05211
    Experimental

    It is being developed by Schering-Plough and Pharmacopeia. Little information has been released about PS386113.

  10. Drug

    Tulrampator

    go.drugbank.com/drugs/DB16344
    Investigational

    Tulrampator is under investigation in clinical trial NCT02626572 (Efficacy and Safety of 3 Doses of S47445 Versus Placebo in Patients With Alzheimer's Disease at Mild to Moderate Stages With Depressive